Research programme: antibody therapeutics - Invenra
Latest Information Update: 18 Nov 2022
At a glance
- Originator Invenra
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 13 Oct 2022 Early research in Solid tumours in USA (unspecified route)